Management of Patients with Non-Cystic Fibrosis Bronchiectasis: Reducing Burden of Disease and Addressing Exacerbation and Lung Function
Clinical Update on the Evolving Role of B-Cell Targeting Therapies to Improve Outcomes in Patients with Generalized Myasthenia Gravis
Beyond Symptom Control: Targeting BAFF/APRIL Pathways in Generalized Myasthenia Gravis
The Role of Complement Pathway Inhibitors in the Management of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Clinical Updates for Gene Silencing, RNA Interference Therapies for Transthyretin Amyloid Disease
Management of Patients with Non-Cystic Fibrosis Bronchiectasis: Reducing Burden of Disease and Addressing Exacerbation and Lung Function
The Role of Complement Pathway Inhibitors in the Management of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Will We See a New Paradigm for SPAF? Which Patients Are More Likely to Benefit from FXIa Inhibition vs DOACs?
Live from IMS 2026: EXCALIBER-RRMM: First Phase 3 CELMoD Data With MRD-Negative CR as a Dual Primary Endpoint in RRMM
Des experts internationaux évaluent de nouvelles données sur l’inhibition de l’aldostérone synthase dans la prise en charge de l’hypertension difficile à contrôler, à l’intention des professionnels de santé de premier recours
Integrating Next-Generation Acid Suppression into Practical Algorithms for Gastroenterologists
PCSK9 Inhibitors in Primary Prevention: A New Paradigm for Family Physicians
The Evolving Role of High Efficacy, Anti-CD40 Therapeutics for Relapsing Multiple Sclerosis
Review of Biosimilar Therapeutics for Patients with Relapsing Multiple Sclerosis
Update on Clinical Data and Applications for Anti-CD20 Therapeutics to Treat Relapsing Multiple Sclerosis
What Every Family Medicine Physician Should Know About Hepatic Encephalopathy: Recognition, Differential Diagnosis, Diagnostic Testing, and Appropriate Referral
EHA2026: New Data on the Management of Anemia in Myelofibrosis
Novel B-Cell Depleting Targeted Therapies to Improve Outcomes in Patients With Sjögren’s Disease
Novel B-Cell Depleting Targeted Therapies to Improve Outcomes in Patients With Sjögren’s Disease
Re Engineering B Cell Signaling in Sjögren’s Disease: BAFF/APRIL Blockade as a New Path to Durable Disease Control
